HER2 overexpressing breast cancer: novel therapeutic strategies

Natural history of HER2-positive disease has changed dramatically over the last 10 years with the advent of HER2-targeted therapies.

This has resulted in HER2-positive early-stage disease becoming a highly curable disease

We have now quite specific areas of need which we have learnt from other studies:

  • CNS disease
  • Cancers with Pi3K pathway alterations
  • Low HER2 expression and
  • Low levels of immune infiltrates
  • ER status

A review of some of these studies is presented

This event is sponsored by: :



Sherene Loi MBBS (Hons), PhD, FRACP, FAHMS

Medical Oncologist and & Head, Breast Cancer ...

Melbourne, VICTORIA, Australia

Professor Sherene Loi's research interest is to translate interesting scientific findings into innovative treatment approaches.

Comments (0)